Articles

The new Cancer Drugs Fund: sticking plaster 2.0 or a model for the fut…

12th February 2016

The new Cancer Drugs Fund: sticking plaster 2.0 or a model for the future?Andrew McConaghie

A new, value-based Cancer Drugs Fund is set to be launched in England soon, but pharma companies fear it will be a step backwards for access to new cancer medicines. Andrew... Read more

What doctors say about that Super Bowl OIC ad

11th February 2016

What doctors say about that Super Bowl OIC adDaniel Ghinn

Daniel Ghinn examines the social media conversations around an advertisement for opioid-induced constipation that was aired during the final of the hugely popular American football championship in the US last... Read more

Pre-exposure treatment to help prevent HIV

10th February 2016

Pre-exposure treatment to help prevent HIVDavid Rowlands

Wider use of Pre-Exposure Prophylaxis (PrEP), where people who don't have HIV take a pill every day, could prevent around 7,400 new HIV infections in the UK by 2020. David... Read more

Teva: looking for innovation and growth in ‘space between’ branded and…

9th February 2016

Teva: looking for innovation and growth in ‘space between’ branded and genericsAndrew McConaghie

Teva is looking to evolve its business through new R&D programmes and development of 'New Therapeutic Entities' from off-patent drugs. Andrew McConaghie speaks to the company's Richard Malamut about how... Read more

News

Amgen steals a march on Sanofi with Repatha NICE approval

9th February 2016

Amgen steals a march on Sanofi with Repatha NICE approvalAndrew McConaghie

Amgen has secured a recommendation for its new cholesterol drug Repatha (evolocumab) from NICE, giving it a major advantage on Sanofi/Regeneron's rival Praluent (alirocumab).NICE rejected any use of Repatha on... Read more

Cancer Drugs Fund needs better management, say MPs

5th February 2016

Cancer Drugs Fund needs better management, say MPsMarco Ricci

NHS England has been criticised for having not tracked the benefits to patients of the Cancer Drugs Fund (CDF) and the money spent on it.The House of Commons Public Accounts... Read more

AstraZeneca: UK is better off in Europe

4th February 2016

AstraZeneca: UK is better off in EuropeAndrew McConaghie

UK-headquartered pharma company AstraZeneca has weighed into the debate about the country's place in the European Union, saying it supports staying in the trading bloc.Britain's Prime Minister David Cameron is... Read more

Sanofi Pasteur commits to development of Zika vaccine

4th February 2016

Sanofi Pasteur commits to development of Zika vaccineMarco Ricci

Sanofi Pasteur – Sanofi's vaccine division – has launched a research and development programme to develop a vaccine against the Zika virus.The company already markets vaccines for yellow fever, Japanese... Read more

Audio & Video

Live webinar – Patient centricity 101: H…

BrightTALK holding slide SDL 23 Feb 12.02.16 v2 

According to the European Commission and NIHR Clinical Research Network, between 2007 and 2011,... View more

Available on demand: Why the success of …

BrightTALK holding slide IMS 04 12 2015-4-3version sw LB

 

This webinar is the first in a series of webinars focused on the topic: Unlocking the... View more

Available on demand – Predicting success…

BrightTALK holding slide Cello v1 30.11.2015

 

The current market research climate in the pharmaceutical industry is one of "doing more with less". At the same... View more

Available on demand – Digital healthcare…

BrightTALK holding slide 23 11 2015

 

So, we are finally at a point where with some certainty we can confirm we are in a digital world... View more

White Papers

Patient centricity: How does Boehringer …

Patient centricity: How does Boehringer Ingelheim UK measure up?Alan Sumner

Patient centricity is a subject that is massively talked about but few can 'walk the talk'. Fewer still can demonstrate what that walk has achieved and where it is headed.

In 2015 Boehringer Ingelheim UK... View info

From promise to practice: immuno-oncolog…

From promise to practice: immuno-oncology in action – the new frontier in cancer treatment

Immuno-oncology therapies that harness the body's own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment.

Clinical trials of emerging products, both alone... View info

Doctors on the front line of healthcare …

Doctors on the front line of healthcare evolution - Whitepaper - The digital health debate

Advances in digital technology have become ubiquitous within healthcare, bringing about breakthroughs in diagnosis, new treatment options and at the same time heralding the expansion of companies usually associated with... View info

Pricing & Market Access Outlook 2015…

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet... View info

Further News & Articles

End-of-life treatments: what will NICE accept?

As consultation on the 'new' Cancer Drugs Fund closes this week, Leela Barham reviews the impact of England's gui... Read more

Articles

Hooray for patient engagement teams

Patient advocate Andrew Schorr welcomes pharma's efforts to listen to, and work with, patients and calls for company... Read more

Articles

Patient perspective: a breast cancer diagnosis

On World Cancer Day, we relate the personal 'diary' experience of an American woman diagnosed with breast cancer.Read more

Articles

AZ shows progress, but Crestor loss will see it shrink in 2016

AstraZeneca (AZ) is making strong progress in re-building its drug portfolio, but 2016 will see revenues and pro... Read more

News

Pharma’s crippling addiction and how to cure it

The 'find it, file it, flog it' approach to drug development has to be abandoned for a truly patient-centred appr... Read more

Articles

Allergan deal will go ahead, says Pfizer chief

Pfizer's chief executive Ian Read says his company's $160 billion takeover of Allergan will not be blocked by US... Read more

News

It is impossible to seduce or a delicious dinner, no new postures, and you do not have the patience to put up with having sex once a week? Try Generic Cialis - Often it happens that because of their age or for other reasons, men lose their potency, and against the background of everyday affairs, interest in his personal life is gradually fading. The disease is or penalty for excessive activity at a young age, it's up to you! With Generic Viagra treatment you will keep your potency at the highest level!